ROTH Capital initiated coverage on BioAtla with a new price target
$BCAB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
ROTH Capital initiated coverage of BioAtla with a rating of Buy and set a new price target of $75.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2024 | Buy → Neutral | H.C. Wainwright | |
| 9/15/2022 | $17.00 | Mkt Outperform | JMP Securities |
| 5/5/2022 | $35.00 → $5.00 | Outperform → Neutral | Credit Suisse |
| 3/21/2022 | $25.00 | Buy | H.C. Wainwright |
| 10/15/2021 | $68.00 | Buy | BTIG Research |
| 6/28/2021 | $75.00 | Buy | ROTH Capital |
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
Ozuriftamab vedotin, the Company's conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in treatment-refractory patients with squamous cell carcinoma of the head and neck (SCCHN) in its Phase 2 clinical trial The Company is on track to meet with the FDA for guidance on a potentially registrational trial in 2H 2024SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Dr
JMP Securities analyst Reni Benjamin maintains BioAtla (NASDAQ:BCAB) with a Market Outperform and lowers the price target from $12 to $5.
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
10-Q - BioAtla, Inc. (0001826892) (Filer)
8-K - BioAtla, Inc. (0001826892) (Filer)
8-K - BioAtla, Inc. (0001826892) (Filer)
SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board. Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the "FDA") regarding our proposed pivotal trial in second-line (2L) plus SCCHNEvalstotug (CAB-CTLA-4) in combination with PD-1 demonstrates tumor reduction in all eight, first-line unresectable or metastatic melanoma patients with 4 responses including a complete response (CR), ongoing, with relatively low incidence and severity of immune-related adverse events;
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, November 7, 2024Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2024 Earnings Conference Call Dial-in Numbers: (800) 343-4136 (domestic), (203) 518-9848 (internationa
Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug (CAB-CTLA-4 antibody) demonstrated a similar low incidence and severity of immune-related adverse events across both Phase 1 and 2 studies; Phase 2 combination with pembrolizumab study continues to enroll and on track for initial data readout in 2H 2024Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 trial in NSCLC showed trend for improved overall survival among treated patients with tumors expressing mutated KRAS variants compared to KRAS wildtype; anti-tumor activity across multiple KR
H.C. Wainwright downgraded BioAtla from Buy to Neutral
JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00
Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the "FDA") regarding our proposed pivotal trial in second-line (2L) plus SCCHNEvalstotug (CAB-CTLA-4) in combination with PD-1 demonstrates tumor reduction in all eight, first-line unresectable or metastatic melanoma patients with 4 responses including a complete response (CR), ongoing, with relatively low incidence and severity of immune-related adverse events;
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, November 7, 2024Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2024 Earnings Conference Call Dial-in Numbers: (800) 343-4136 (domestic), (203) 518-9848 (internationa
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title: Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumorsAuthors: Jacob Thomas, Eva Selfridge, Costantine Alba